Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2007-12-04 Capital/Financing Update
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Appendix 3B 10 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used for announcements related to new issues of securities, applications for quotation of additional securities, and related agreements. It details the issuance of ordinary shares, the number of securities issued, issue price, purpose of the issue, and other related information. It also includes a notice under Section 708A(5)(e) of the Corporations Act 2001 regarding the issue of shares without a disclosure document, which is a regulatory compliance announcement. The document does not contain financial statements, management discussion, or detailed financial results, but rather focuses on capital raising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the securities issued and related compliance, confirming it is not merely an announcement of a report but a substantive filing about capital changes.
2007-12-04 English
LCT Receives A$6.0 M In Capital Placement 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Living Cell Technologies Ltd dated November 30, 2007, regarding the receipt of A$6.0 million in capital placement funds. It details the subscription of new ordinary shares and mentions the company's financial position and clinical trials. There is no detailed financial report, earnings data, or management discussion of financial results. The document is focused on capital raising activity and financing updates. The length is 4113 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2007-11-29 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares and options acquired or disposed of. The content is focused on reporting personal share transactions by a company director. The document length is 3609 characters, which is consistent with a detailed notice rather than a brief announcement. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades).
2007-11-29 English
LCT Updates Shareholders on Clinical Trial Progress at AGM 2 pages ?Kb
AGM Information Classification · 95% confidence The document is a company announcement providing an update to shareholders on clinical trial progress at the Annual General Meeting (AGM). It discusses clinical trial milestones, patient progress, and future plans, but does not contain financial statements or detailed financial data. The document is clearly linked to the AGM event and serves as information shared during that meeting rather than a full annual report or financial filing. The length is under 5,000 characters and it is a direct update rather than a report publication announcement. Therefore, the document fits best under AGM Information (AGM-R).
2007-11-26 English
Living Cell Technologies AGM 13 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed presentation from November 2007 about DiabeCell®, a product pipeline update from LCT. It includes forward-looking statements, milestones, clinical trial phases, commercial strategy, financial milestones, and future targets. The content is structured as a corporate presentation with slides covering technology, market positioning, clinical trials, manufacturing, and financial plans. There is no indication that this is a formal regulatory filing, annual or interim report, earnings release, or audit report. The document is not a transcript, nor does it announce voting results or management changes. It is clearly an investor-focused presentation providing detailed information on the company's products, strategy, and financial outlook. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (8578 characters) supports it being a full presentation rather than a brief announcement.
2007-11-26 English
Results of AGM Held on 27 November 2007 3 pages ?Kb
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of Annual General Meeting held on 27 November 2007' and contains detailed voting results for multiple resolutions passed at the AGM, including election and re-election of directors, approval of remuneration report, and other shareholder resolutions. It references the Corporations Act and ASX Listing Rules, indicating it is an official announcement of voting outcomes. The content is focused on the results of shareholder votes rather than the full AGM materials or the annual report itself. The document length is about 5,341 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2007-11-26 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.